Hello and welcome to the AIM ImmunoTech fourth-quarter and full-year 2024 update conference call and webcast. (Operator Instructions) Note that this webcast is being recorded at the company's request, ...

Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.